BR9306345A - Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune - Google Patents
Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imuneInfo
- Publication number
- BR9306345A BR9306345A BR9306345A BR9306345A BR9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- suppressing
- proliferate
- cells
- ability
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 8
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87128992A | 1992-04-20 | 1992-04-20 | |
| US96177992A | 1992-10-15 | 1992-10-15 | |
| US97773792A | 1992-11-13 | 1992-11-13 | |
| US08/027,127 US5593698A (en) | 1990-10-31 | 1993-03-05 | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| PCT/US1993/003708 WO1993020842A1 (en) | 1992-04-20 | 1993-04-20 | Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9306345A true BR9306345A (pt) | 1998-06-30 |
Family
ID=27487557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9306345A BR9306345A (pt) | 1992-04-20 | 1993-04-20 | Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5593698A (pt) |
| EP (1) | EP0637249B1 (pt) |
| JP (1) | JPH07505892A (pt) |
| KR (1) | KR100275656B1 (pt) |
| AT (1) | ATE205400T1 (pt) |
| AU (1) | AU686101B2 (pt) |
| BR (1) | BR9306345A (pt) |
| CA (1) | CA2118502A1 (pt) |
| DE (1) | DE69330752D1 (pt) |
| HU (1) | HUT71310A (pt) |
| IL (1) | IL105472A (pt) |
| NO (1) | NO943967L (pt) |
| WO (1) | WO1993020842A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| US6156306A (en) * | 1994-08-17 | 2000-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pancreatic β-cells for allogeneic transplantation without immunosuppression |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| US7361331B2 (en) * | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| US7348005B2 (en) * | 2000-03-15 | 2008-03-25 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| WO2001076617A2 (en) * | 2000-03-15 | 2001-10-18 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| AU6481301A (en) | 2000-05-24 | 2001-12-03 | Us Health | Methods for preventing strokes by inducing tolerance to e-selectin |
| HU229489B1 (hu) | 2000-08-21 | 2014-01-28 | Apitope Technology Bristol Ltd | Tolerogén peptidek |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| WO2004045376A2 (en) * | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| DK2083856T3 (da) | 2007-08-15 | 2011-01-24 | Circassia Ltd | Peptider til desensibilisering mod allergener |
| PT2953634T (pt) | 2013-02-07 | 2021-09-02 | Massachusetts Gen Hospital | Métodos de expansão ou depleção das células t reguladoras |
| CN111239415B (zh) | 2013-10-17 | 2024-03-26 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| EP3126374B1 (en) * | 2014-04-01 | 2018-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An isolated donor mhc-derived peptide and uses thereof |
| AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
| EP3455262A4 (en) | 2016-05-13 | 2020-04-08 | The General Hospital Corporation | ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES |
| CN113302205B (zh) | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364762A (en) * | 1990-03-21 | 1994-11-15 | Board Of Trustees Of The Leland Stanford Junior University | Major histocompatibility complex (MHC) molecules |
-
1993
- 1993-03-05 US US08/027,127 patent/US5593698A/en not_active Expired - Fee Related
- 1993-04-20 IL IL10547293A patent/IL105472A/en not_active IP Right Cessation
- 1993-04-20 CA CA002118502A patent/CA2118502A1/en not_active Abandoned
- 1993-04-20 DE DE69330752T patent/DE69330752D1/de not_active Expired - Lifetime
- 1993-04-20 AU AU41083/93A patent/AU686101B2/en not_active Ceased
- 1993-04-20 JP JP5518673A patent/JPH07505892A/ja not_active Ceased
- 1993-04-20 EP EP93910671A patent/EP0637249B1/en not_active Expired - Lifetime
- 1993-04-20 AT AT93910671T patent/ATE205400T1/de not_active IP Right Cessation
- 1993-04-20 KR KR1019940703715A patent/KR100275656B1/ko not_active Expired - Fee Related
- 1993-04-20 BR BR9306345A patent/BR9306345A/pt not_active Application Discontinuation
- 1993-04-20 WO PCT/US1993/003708 patent/WO1993020842A1/en not_active Ceased
- 1993-04-20 HU HU9403006A patent/HUT71310A/hu unknown
-
1994
- 1994-10-19 NO NO943967A patent/NO943967L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO943967D0 (no) | 1994-10-19 |
| EP0637249A1 (en) | 1995-02-08 |
| CA2118502A1 (en) | 1993-10-28 |
| HUT71310A (en) | 1995-11-28 |
| EP0637249B1 (en) | 2001-09-12 |
| HU9403006D0 (en) | 1994-12-28 |
| ATE205400T1 (de) | 2001-09-15 |
| JPH07505892A (ja) | 1995-06-29 |
| AU686101B2 (en) | 1998-02-05 |
| NO943967L (no) | 1994-10-19 |
| KR950701228A (ko) | 1995-03-23 |
| EP0637249A4 (en) | 1997-01-08 |
| KR100275656B1 (ko) | 2000-12-15 |
| AU4108393A (en) | 1993-11-18 |
| US5593698A (en) | 1997-01-14 |
| IL105472A0 (en) | 1993-08-18 |
| WO1993020842A1 (en) | 1993-10-28 |
| IL105472A (en) | 1999-06-20 |
| DE69330752D1 (de) | 2001-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9306345A (pt) | Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune | |
| Selby et al. | The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation | |
| PT735893E (pt) | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária | |
| CA2093513A1 (en) | Methods and compositions for suppressing allograft rejection in mammals | |
| MD970009A (en) | Methods for inducing T cells tolerance to donor tissues or organs | |
| ES2149276T3 (es) | Imidazo(4,5-c)piridin-4-aminas. | |
| ES2150496T3 (es) | Cicloalquilimidazopiridinas condensadas. | |
| MX9702932A (es) | L-ribofuranosilnucleosidos. | |
| ES2087163T3 (es) | Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2. | |
| ZA90241B (en) | Therapeutic compositions comprising s-adenosyl-methionine and use of the same in the therapeutic treatment of pancreatitis and of the immuno rejection in the pancreas transplant | |
| GR3027668T3 (en) | Immunosuppressive compositions | |
| FI962550A0 (fi) | Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa | |
| BG93298A (bg) | Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни | |
| WO1993006852A3 (en) | Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein | |
| CA2157500A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation | |
| AR002005A1 (es) | Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora, procedimiento para su preparacion, composicion farmaceutica que loscontiene y metodo para la supresion de la respuesta inmune. | |
| Bastos et al. | Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity | |
| NZ234451A (en) | Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions | |
| Piatier-Tonneau et al. | T suppressor lymphocytes regulation of adjuvant arthritis in two inbred strains of rats | |
| EP0959899A4 (en) | LO-CD2a antibodies and their use to inhibit T-cell activation and proliferation | |
| Yachnin et al. | Inhibition of human lymphocyte transformation by human α-fetoprotein (HAFP); HAFP monomers and multimers and a resistant lymphocyte subpopulation | |
| MX9202643A (es) | Peptidos utiles en la regulacion de los sistemas inmunologico y nervioso. | |
| EP0249502A3 (en) | Soluble immune suppressor factor and suppressor cells | |
| Allan et al. | In vivo studies on suppressor lymphocyte activity following administration of Escherichia coli O138 lipopolysaccharide | |
| Schoof | Murine Leukocyte proliferation following topical application of tumor promoters and other inflammatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FC | Decision: refusal | ||
| FC | Decision: refusal |